Jack Heptinstall

Also affiliated with Duke Medical Center

Immunology and MicrobiologyMedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 25 papers. Top paper: “Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein”.

Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein

Clinical Infectious Diseases(2020)10.1093/cid/ciz1239

N/A

1.2DataRank · unranked

35 citations

Craig Innes, Sarita Naidoo, Philipp Mann, Julia Hütter, Gita Ramjee +69 more

Analysis of the HIV Vaccine Trials Network 702 Phase 2b–3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk

The Journal of Infectious Diseases(2022)10.1093/infdis/jiac260

N/A

1.1DataRank · unranked

50 citations

One Dintwe, Sheetal Sawant, Doug Grove, Yunda Huang, Holly Janes +43 more

Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial

The Lancet HIV(2023)10.1016/s2352-3018(23)00140-6

N/A

1.1DataRank · unranked

33 citations

Sharon Mannheimer, Carmen A. Paez, Chenchen Yu, Theresa Gamble, Deborah Theodore +22 more

Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study

The Journal of Infectious Diseases(2022)10.1093/infdis/jiac445

N/A

0.872DataRank · unranked

36 citations

Dan H. Barouch, Christy Comeaux, Michal Sarnecki, Kathryn E. Stephenson, Stephen R. Walsh +43 more

Safety and immunogenicity of a polyvalent DNA–protein HIV vaccine with matched Env immunogens delivered as a prime–boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial

The Lancet HIV(2024)10.1016/s2352-3018(24)00036-5

N/A

0.530DataRank · unranked

10 citations

Shuying S. Li, Nicole Grunenberg, Edgar T. Overton, Samuel T. Robinson, Hua Zheng +20 more

Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial

PLoS Medicine(2024)10.1371/journal.pmed.1004360

N/A

0.439DataRank · unranked

9 citations

Erica Andersen‐Nissen, Nicole Grunenberg, One Dintwe, Faatima Laher Omar, Jia Jin Kee +29 more

Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial

The Lancet HIV(2024)10.1016/s2352-3018(24)00247-9

N/A

0.381DataRank · unranked

11 citations

Christopher B. Hurt, Kathryn E. Stephenson, Yunda Huang, Carmen A. Paez, Chenchen Yu +95 more

Focusing HIV-1 Gag T cell responses to highly conserved regions by DNA vaccination in HVTN 119

JCI Insight(2024)10.1172/jci.insight.180819

N/A

0.356DataRank · unranked

8 citations

Barbara K. Felber, James I. Mullins, Hyman Scott, Mary Allen, Stephen C. De Rosa +14 more

Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial

The Lancet HIV(2025)10.1016/s2352-3018(25)00012-8

N/A

0.292DataRank · unranked

6 citations

Carmen A. Paez, Chenchen Yu, Shelly Karuna, Theresa Gamble, Maurine D. Miner +32 more

A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials

Emerging Microbes & Infections(2025)10.1080/22221751.2025.2485317

N/A

0.260DataRank · unranked

4 citations

Shuying Sue Li, Elena Giorgi, LaTonya D. Williams, One Dintwe, Lindsay N. Carpp +34 more

Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1–2 randomized double-blind placebo-controlled trial

PLOS Global Public Health(2024)10.1371/journal.pgph.0003319

N/A

0.108DataRank · unranked

1 citations

Fatima Laher, Linda‐Gail Bekker, Kelly E. Seaton, Mary Allen, Stephen De Rosa +27 more

HVTN 123: A Phase 1, Randomized Trial Comparing Safety and Immunogenicity of CH505TF gp120 Produced by Stably and Transiently Transfected Cell Lines

The Journal of Infectious Diseases(2024)10.1093/infdis/jiae558

N/A

0DataRank · unranked

0 citations

L. W. Preston Church, Colleen F. Kelley, Samuel T. Robinson, Yiwen Lu, Briana D. Furch +13 more

Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV

Nature Communications(2025)10.1038/s41467-025-63948-4

N/A

0DataRank · unranked

1 citations

Bo Zhang, Caroline Brackett, Peter Elyanu, Asa Tapley, Sufia Dadabhai +95 more

Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials

PLoS Medicine(2020)10.1371/journal.pmed.1003117

N/A

0DataRank · unranked

14 citations

Stephen R. Walsh, Fatima Laher, Lucas Maganga, Michael E. Herce, Sarita Naidoo +28 more

Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition

UNC Libraries(2025)10.17615/19xw-z883

N/A

0DataRank · unranked

0 citations

José A. Hidalgo, Fatima Laher, John Hural, Nicole L. Yates, Caroline Brackett +40 more

Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV-1 Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523-LS

Frontiers in Immunology(2021)10.3389/fimmu.2021.709994

N/A

0DataRank · unranked

17 citations

Kelvin Chiong, Kelly E. Seaton, Christine A. Arocena, Sheetal Sawant, Jonathan Hare +11 more

Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans

npj Vaccines(2021)10.1038/s41541-021-00305-8

N/A

0DataRank · unranked

15 citations

Aaron Deal, Xue Han, Shuying S. Li, Ashley Clayton, Jack Heptinstall +25 more

Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition

Nature Medicine(2022)10.1038/s41591-022-01953-6

N/A

0DataRank · unranked

129 citations

Yunda Huang, Allan C. deCamp, Shelly Karuna, Yuanyuan Zhang, Craig A. Magaret +42 more

Lower SARS-CoV-2–specific humoral immunity in people living with HIV-1 recovered from nonhospitalized COVID-19

JCI Insight(2022)10.1172/jci.insight.158402

N/A

0DataRank · unranked

21 citations

Shelly Karuna, Caroline Brackett, Martina S. Wesley, Shuying S. Li, Nathan Eisel +20 more

Multi-trial analysis of HIV-1 envelope gp41-reactive antibodies among global recipients of candidate HIV-1 vaccines

Frontiers in Immunology(2022)10.3389/fimmu.2022.983313

N/A

0DataRank · unranked

6 citations

Andrew M. Johnson, Nicole Potchen, Simon S. Minot, Jack Heptinstall, Kelly E. Seaton +6 more

Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition

EBioMedicine(2023)10.1016/j.ebiom.2023.104590

N/A

0DataRank · unranked

33 citations

Yunda Huang, Shelly Karuna, Jack Heptinstall, Caroline Brackett, Kelvin Chiong +40 more

The immunogenicity of an HIV-1 Gag conserved element DNA vaccine in people with HIV and receiving antiretroviral therapy

AIDS(2023)10.1097/qad.0000000000003804

N/A

0DataRank · unranked

9 citations

Barbara K. Felber, Huichao Chen, George N. Pavlakis, James I. Mullins, Stephen C. De Rosa +24 more

Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition

UNC Libraries(2023)10.17615/5a1m-e268

N/A

0DataRank · unranked

0 citations

Wang Yao Feng, D.C. Montefiori, Haajira Kaldine, Valerie Bekker, Georgia D. Tomaras +41 more

Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study

EBioMedicine(2024)10.1016/j.ebiom.2024.105320

N/A

0DataRank · unranked

16 citations

Janine van Duijn, One Dintwe, Jack Heptinstall, Randy I. Burnham, Sheetal Sawant +93 more

Probing Dermal Immunity to Mycobacteria through a Controlled Human Infection Model

ImmunoHorizons(2024)10.4049/immunohorizons.2400053

N/A

0DataRank · unranked

1 citations

Emma Bishop, Andrew Fioré-Gartland, Krystle K. Q. Yu, Ming Chang, Richard M. Jones +20 more